ByTrending Posts
Can AstraZeneca’s $50B US Investment and Eli Lilly’s…
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Cambridge and A*STAR’s New AI Digital Twin…
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
Can Roche’s $700M Genentech Facility Drive Its $50B…
Key Highlights Strategic Expansion into US ManufacturingGenentech, Roche’s US subsidiary, has broken ground on a new $700M state-of-the-art…
Can Novartis and BioArctic’s $802M Alliance Unlock the…
Key Highlights Strategic Collaboration Targets Neurodegenerative DiseasesNovartis has entered into a research partnership with Sweden’s BioArctic, committing $30M…
Can IQVIA and Flagship Pioneering’s AI-Driven Alliance Unlock…
Key Highlights AI-Powered Acceleration in Drug DevelopmentThe collaboration positions IQVIA’s Healthcare-grade AI® and data-driven analytics at the center…
Could Halda Therapeutics and VantAI’s $1B AI Alliance…
Key Highlights Strategic Alliance to Advance Induced Proximity TherapiesHalda Therapeutics has entered into a collaboration with AI biotech…
How AbbVie Is Expanding Its Psychiatry Pipeline Through…
Key Highlights The Promise of BretisilocinBretisilocin (GM-2505) is a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser designed…
Can Novartis’ 19 New Cardiovascular Studies at ESC…
Key Insights Leqvio: Can Inclisiran’s Expanding Role Become a Game-Changer in Cholesterol Management?Novartis is spotlighting the VICTORION-Difference study,…
Will MEDvidi’s AI Clinician and AI Receptionist Set…
MEDvidi, a platform for delivering remote, personalized mental health treatment, is launching AI-powered healthcare solutions for telemedicine platforms.…
Trending Posts
Latest Stories
How Will Hippocratic AI Leverage Grove AI to Accelerate Trial Efficiency and Patient Engagement?
January 22, 2026 — Global — BioNexAI Market Insights reports that Hippocratic AI, a leading…
Is Novartis Bolstering Its Radioligand Oncology Pipeline at JPM 2026 with a Radioligand Peptide Program Acquisition?
Basel / San Francisco | January 2026 Novartis has expanded its precision oncology strategy with a…
Is Pfizer’s $10 Billion Metsera Acquisition at JPM2026 a Defining Move in the Obesity and Cardiometabolic Race?
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move…
Is Amgen Bolstering Its Oncology Pipeline at JPM 2026 with an $840 Million Dark Blue Therapeutics Acquisition?
Thousand Oaks, U.S. | January 2026 Amgen has expanded its oncology growth strategy with the…
Gallery
